(Q37856254)

24 August 2017

title

Rifalazil retains activity against rifampin-resistant mutants of Chlamydia pneumoniae (English)

1 reference

24 August 2017

Chlamydia pneumoniae

1 reference

David M Rothstein

1

1 reference

24 August 2017

Robert J Suchland

2

1 reference

24 August 2017

Minsheng Xia

3

1 reference

24 August 2017

Christopher K Murphy

4

1 reference

24 August 2017

Walter E Stamm

5

1 reference

24 August 2017

publication date

1 August 2008

1 reference

The Journal of Antibiotics

24 August 2017

published in

1 reference

24 August 2017

volume

61

1 reference

24 August 2017

issue

8

1 reference

24 August 2017

page(s)

489-495

1 reference

https://scigraph.springernature.com/pub.10.1038/ja.2008.65

24 August 2017

exact match

0 references

cites work

Mechanism of action of antimycobacterial activity of the new benzoxazinorifamycin KRM-1648

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

Safety and bactericidal activity of rifalazil in patients with pulmonary tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Development potential of rifalazil

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

In vitro activities of rifamycin derivatives ABI-1648 (Rifalazil, KRM-1648), ABI-1657, and ABI-1131 against Chlamydia trachomatis and recent clinical isolates of Chlamydia pneumoniae

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Efficacy of benzoxazinorifamycins in a mouse model of Chlamydia pneumoniae lung infection

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Azithromycin in control of trachoma

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Chlamydia pneumoniae, strain TWAR pneumonia

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Global transcriptional upregulation in the absence of increased translation in Chlamydia during IFNgamma-mediated host cell tryptophan starvation

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Pharmacokinetics of KRM-1648, a new benzoxazinorifamycin, in rats and dogs

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Development potential of rifalazil and other benzoxazinorifamycins

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

A randomized, double-blind study comparing single-dose rifalazil with single-dose azithromycin for the empirical treatment of nongonococcal urethritis in men.

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Rifalazil and other benzoxazinorifamycins in the treatment of chlamydia-based persistent infections

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Comparative antimycobacterial activities of rifampin, rifapentine, and KRM-1648 against a collection of rifampin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Molecular characterization of rpoB mutations conferring cross-resistance to rifamycins on methicillin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Differential effect of rpoB mutations on antibacterial activities of rifampicin and KRM-1648 against Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Activity of novel benzoxazinorifamycins against rifamycin-resistant Streptococcus pyogenes

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Rifampin-resistant RNA polymerase mutants of Chlamydia trachomatis remain susceptible to the ansamycin rifalazil

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Emergence of resistance to rifampin and rifalazil in Chlamydophila pneumoniae and Chlamydia trachomatis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Methodologies and cell lines used for antimicrobial susceptibility testing of Chlamydia spp

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Rifalazil pretreatment of mammalian cell cultures prevents subsequent Chlamydia infection

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Structural mechanism for rifampicin inhibition of bacterial rna polymerase

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Activities of rifamycin derivatives against wild-type and rpoB mutants of Chlamydia trachomatis

1 reference

https://api.crossref.org/works/10.1038%2FJA.2008.65

7 January 2021

Identifiers

DOI

10.1038/JA.2008.65

1 reference

Dimensions Publication ID

24 August 2017

1010868016

0 references

1 reference